Form 4: NewAmsterdam Pharma Co N.V. Officer Kling Sells Shares Under 10b5-1 Plan
SEC Form 4 Filing
Douglas F. Kling, Chief Operating Officer of NewAmsterdam Pharma Co N.V., sold 99,090 and 910 ordinary shares at prices ranging from $15.70 to $16.88, and exercised options to acquire 100,000 shares at $10.
Summary
- On April 15, 2025, Douglas F. Kling, the Chief Operating Officer of NewAmsterdam Pharma Co N.V., engaged in transactions involving the company's ordinary shares.
- Kling exercised an option to acquire 100,000 ordinary shares at a price of $10 per share.
- He also sold 99,090 ordinary shares at prices ranging from $15.70 to $16.65 per share and 910 ordinary shares at prices ranging from $16.70 to $16.88 per share.
- Following these transactions, Kling directly owns 44,000 ordinary shares and 550,930 derivative securities.
Sentiment
Score: 5
Explanation: This is a neutral disclosure of insider trading activity. The sales are conducted under a pre-arranged plan, suggesting no particular bullish or bearish sentiment.
Industry Context
This filing is a routine disclosure of insider trading activity. It's common for executives to exercise stock options and sell a portion of the acquired shares, often under pre-arranged trading plans to avoid accusations of trading on inside information.
Comparison to Industry Standards
- Insider trading activity is a common occurrence in publicly traded companies.
- The use of 10b5-1 trading plans is a standard practice to provide a defense against accusations of illegal insider trading.
- Comparable companies such as Madrigal Pharmaceuticals, Viking Therapeutics, and Akero Therapeutics also experience similar insider trading activities which are publicly disclosed through Form 4 filings.
Stakeholder Impact
- The share sales could exert downward pressure on the stock price, but the impact is likely to be minimal given the relatively small volume and the pre-planned nature of the transactions.
Key Dates
| Date | Description |
|---|---|
| 11/22/2022 | Option granted to Kling. |
| 12/22/2022 | First vesting date of the option (1/48th of shares). |
| 04/15/2025 | Date of the reported transactions: option exercise and share sales. |
| 04/17/2025 | Date of Form 4 filing. |
| 11/22/2032 | Expiration date of the option. |
Keywords
Form 4, insider trading, share sale, option exercise, Douglas F. Kling, NewAmsterdam Pharma, NAMS, COO
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.